secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001437749-25-032662
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharma: INTASYL PH-762 shows 100% tumor clearance in one cSCC patient; SMC clearance safe
--------------------------------------------------------------------------------

- 100% pathologic complete response in 1 of 3 cSCC patients at Day 36 in final dose cohort; >90% clearance in second, >50% in third.
- Safety Monitoring Committee issued favorable review, no dose-limiting toxicities at max dose; PH-762 well tolerated across 5 cohorts.
- Cumulative Phase 1b data: 6 complete, 2 near-complete, 2 partial responses among 16 cSCC patients; no clinical progression.
- CEO notes PH-762 is promising non-surgical alternative for cutaneous carcinomas; trial continues to screen additional patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000143774925032662/0001437749-25-032662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000143774925032662/phio20251023_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-032662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer